Our 2nd golden ticket winner for Uromigos Nashville’23 is Vadim Koshkin Vadim Koshkin MD We are having a livestream debate on the treatment of 1st line bladder cancer (Nov 3rd) as Vadim suggested. Discussion of ESMO23 data. Jonathan Rosenberg MD Shilpa Gupta brando Petros Grivas

After 13 years of graduate/post graduate training, so happy to be hanging up a shingle at UCSFUrology UCSF Helen Diller Family Comprehensive Cancer Ctr Thinking of all my teachers and mentors along the way and grateful to Carroll, Peter Benjamin Breyer for their vision and support. Let’s get to work!

Top 5 #kidneycancer abstracts not to miss ESMO - Eur. Oncology #ESMO23! Belzutifan is everywhere and there's a phase 3 VEGF-IO trial reading out in a Chinese population!! Looking forward to seeing all these data! Kidney Cancer KCCure KidneyCAN KidneyCancerProgram OncoAlert

Belzutifan vs everolimus in pretreated RCC #ESMO23: 25% ⬆️ in PFS, OS HR = 0.88 (95% CI 0.73-1.07) with RR=23% vs 3% & 25-45% ⬆️ in time to ⬇️ QOL. Tox of note: hypoxia. This looks attractive in VEGF/IO refractory disease instead of evero. Combos earlier in the disease awaited.

#Goosebumps #EV302 #ESMO23 Took 3 decades but a new SOC in 1L bladder cancer !!!!!! ⁦Tom Powles⁩ EV+Pembro irrespective…..WOW! 🤩

Zanzalitinib with activity in refractory RCC with manageable safety profile even in those patients who had previously received cabozantinib Sumanta K. Pal, MD, FASCO Toni Choueiri, MD Kidney Cancer

Happy to share our findings at #IKCSNA23! In our single-institution retrospective cohort, no evidence of superiority of either IO/IO or TKI/IO in #kidneycancer 1L tx with regard to PFS2, including in groups w/ sarcomatoid features, BAP1 mutation, or deep RECIST response.

Exited to have Dr. Kelly Fitzgerald Kelly Fitzgerald speak at UCSF #CardioOnc conference this THU. Discussion of RCC/kidney cancer & CardioOnc. Focus on VEGF/HIF inhibitors and immune checkpoints! UCSF Cardiology UCSF Helen Diller Family Comprehensive Cancer Ctr Alan Baik Mandar Aras, MD, PhD

Great news for our patients w #kidneycancer!! Belzutifan now approved in refractory disease based on #LITESPARK005 data from Laurence Albiges et al. KCCure Kidney Cancer KidneyCAN

Big news for bladder cancer in US! “On December 15, 2023, the Food and Drug Administration (FDA) approved enfortumab vedotin-ejfv in combination with pembrolizumab for patients with locally advanced or metastatic urothelial cancer (la/mUC).”

Thoroughly enjoyed reading this overview of selected molecularly defined aggressive #kidneycancer subtypes by Ying-Bei Chen, MD, PhD 👉 journals.lww.com/anatomicpathol… #RenalMedullaryCarcinoma #RareCancers #HLRCC #endRMC Kidney Cancer RMC Alliance R.M.C. Inc Chris Johnson Foundation Inc. Rare Cancer Research Foundation + Pattern.org

Congrats to Sahil Doshi Sahil Doshi for this retrospective analysis of outcomes on first-line therapy in >100 patients with #chromophobe rcc. Looking forward to seeing longer term follow-up in patients in the doublet cohorts. Martin Voss Nazli Dizman Andy Hahn Andrea Knezevic

Interesting to consider a ‘very favorable risk’ subgroup of ccRCC patients and the role of VEGFR targeted therapies here. How will HIF2a blockade perform in these patients?

Memorial Sloan Kettering Cancer Center cofellows taking in the view at #asco24 Kelly Fitzgerald Yonit Lavin Sherry Shen

Happening Today **Kidney Cancer Association's 2024 Virtual Patient Summit** for education and support! 🎗️🧠 📅 Learn more and register here: [kidneycancer.org/patient-educat…] #KidneyCancer #PatientEducation Kidney Cancer Allison May, MD Rana McKay, MD, FASCO Brian Shuch, MD Kelly Fitzgerald

UPDATE 3/12: Last night the House voted to cut 57% of federally funded medical and cancer research through the CDMRP. Vote moves on to Senate and, if passed, to be signed into law by the President. More details: kidneycancer.org/protect-federa…

Federal #kidneycancer research funding drops from $50 million to ZERO after 57% cut to CDMRP. All but 12 of the 35 disease research programs saw funding eliminated for 2025, including the Kidney Cancer Research Program. More about the impact on our blog. bit.ly/4hoXnCq

(1/3) Check out our multicenter, IIT of sitravatinib + nivolumab after ICI in patients with metastatic ccRCC shorturl.at/qGWgy This trial was terminated early (14 of 88 planned) but built upon our group’s experience with sitravatinib led by Pavlos Msaouel

Interested in myeloid cell anti-tumor immunity? I’ll be presenting at National Cancer Institute Rising Scholars Seminar Series on 17 Apr our work on Fc-optimized CD40 Agonistic Antibody and TLS formation and induction of Systemic Antitumor Immunity cassyni.com/events/Eg84FXZ…

From the May issue: 'Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in RCC brnw.ch/21wSSDz By Miya Hugaboom, Lena Wirth, Kelly Street, Neil Ruthen, Michael Atkins, Catherine Wu, David Braun